Suddenly we’re missing obvious warning signs, ignoring key markers of danger, or simply deciding to take a leap of faith at exactly the wrong moment.
Research admittedly takes a long time, including the need for replication, and patients in clinical programs aren’t necessarily willing to wait.
Suppose we could develop cognitive techniques and train the patient to use them whenever symptoms reappeared?
The relative importance of set and setting suggests that the environment in an LSD experience should be carefully controlled.
I think the problem is I have read the research, and it didn’t confirm the claims made on its behalf.
The increased incidence of depression, anxiety, and other psychiatric symptoms linked to OUD may also help to account for high rates of relapse among patients, post-treatment, versus other substance disorders.
These are questions that come up with every drug, not just cannabis. And unanswered, they can lead to problems down the road.
The public , including those in elected office, seem to assume that the expected prohibition on sales and use by underage persons will somehow be enough to limit the damage.
The field is getting accustomed to patients arriving in addiction treatment complaining of problems with prescription opioids, stimulants, sedatives, etc, while actively enrolled in medical cannabis programs.